Bicycle Therapeutics (BCYC) Price & Analysis

Compare

375 Followers

BCYC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.10 - $28.67

Previous CloseN/A

Volume92.63K

Average Volume (3M)262.63K

Market Cap

$514.17M

Enterprise Value$13.93M

Total Cash (Recent Filing)$792.97M

Total Debt (Recent Filing)$8.32M

Price to Earnings (P/E)―

Beta1.59

Next Earnings

Jul 31, 2025

EPS Estimate

-0.94

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.88

Shares Outstanding47,761,845

10 Day Avg. Volume350,910

30 Day Avg. Volume262,632

Financial Highlights & Ratios

PEG Ratio-0.18

Price to Book (P/B)3.24

Price to Sales (P/S)0.00

P/FCF Ratio-8.35

Enterprise Value/Market Cap0.03

Enterprise Value/Revenue0.10

Enterprise Value/Gross Profit0.69

Enterprise Value/Ebitda-0.02

Forecast

1Y Price Target

$23.14

Price Target Upside211.44% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bicycle Therapeutics News

See All News >

Bulls Say, Bears Say

Bulls Say

Efficacy And Response RatesThe number of confirmed responses increased from 5 to 10 among 20 evaluable patients, demonstrating continued superiority over chemotherapy's 35% overall response rate.

Pipeline DevelopmentThe company is planning to disclose additional data and initiate multiple studies, indicating active development and potential future advancements in their pipeline.

Safety ProfileZelenectide pevedotin continued to show a more favorable safety and tolerability profile vs. Padcev in the combination setting with lower Grade 3+ treatment-related skin reactions.

Bears Say

Earnings ReportThe quarter's earnings report was described as uneventful.

Efficacy ConcernsThe efficacy still falls short of the 64-73% overall response rate seen with Padcev, which has increasingly become the standard of care for 1L metastatic urothelial cancer.

Safety ConcernsThe safety profile has deteriorated with an increased incidence of peripheral neuropathy.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

23.78% Insiders

5.63% Mutual Funds

64.75% Other Institutional Investors

5.07% Public Companies and Individual Investors

Detailed Ownership Overview >

BCYC FAQ

What was Bicycle Therapeutics Ltd’s price range in the past 12 months?

Bicycle Therapeutics Ltd lowest stock price was $6.10 and its highest was $28.67 in the past 12 months.

What is Bicycle Therapeutics Ltd’s market cap?

Bicycle Therapeutics Ltd’s market cap is $514.17M.

When is Bicycle Therapeutics Ltd’s upcoming earnings report date?

Bicycle Therapeutics Ltd’s upcoming earnings report date is Jul 31, 2025 which is in 24 days.

How were Bicycle Therapeutics Ltd’s earnings last quarter?

Bicycle Therapeutics Ltd released its earnings results on May 01, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.842 by -$0.038.

Is Bicycle Therapeutics Ltd overvalued?

According to Wall Street analysts Bicycle Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bicycle Therapeutics Ltd pay dividends?

Bicycle Therapeutics Ltd does not currently pay dividends.

What is Bicycle Therapeutics Ltd’s EPS estimate?

Bicycle Therapeutics Ltd’s EPS estimate is -0.94.

How many shares outstanding does Bicycle Therapeutics Ltd have?

Bicycle Therapeutics Ltd has 47,761,845 shares outstanding.

What happened to Bicycle Therapeutics Ltd’s price movement after its last earnings report?

Bicycle Therapeutics Ltd reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.842. Following the earnings report the stock price went up 6.075%.

Which hedge fund is a major shareholder of Bicycle Therapeutics Ltd?

Currently, no hedge funds are holding shares in BCYC

Bicycle Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-37.13%

Trailing 12-Months

Asset Growth

61.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bicycle Therapeutics Ltd

Bicycle Therapeutics (BCYC) is a clinical-stage biopharmaceutical company specializing in the development of a novel class of medicines, known as Bicycles, for diseases that are underserved by existing therapies. These Bicycles are synthetic short peptides constrained to form two loops, which provide a unique structural stability and high affinity for their targets. The company's primary focus is on oncology, where its proprietary technology is being applied to create targeted therapies aimed at treating cancer more effectively and with fewer side effects compared to traditional treatments.

BCYC Stock 12 Month Forecast

Average Price Target

$23.14

▲(211.44%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","13":"$13","20":"$20","27":"$27","34":"$34"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,13,20,27,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.55,10.430769230769231,12.311538461538461,14.192307692307693,16.073076923076925,17.953846153846154,19.834615384615386,21.715384615384615,23.596153846153847,25.47692307692308,27.357692307692307,29.23846153846154,31.11923076923077,{"y":33,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.55,9.672307692307694,10.794615384615385,11.916923076923077,13.03923076923077,14.161538461538463,15.283846153846154,16.406153846153845,17.52846153846154,18.65076923076923,19.77307692307692,20.895384615384614,22.017692307692307,{"y":23.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.55,8.96923076923077,9.38846153846154,9.807692307692308,10.226923076923077,10.646153846153847,11.065384615384616,11.484615384615385,11.903846153846153,12.323076923076924,12.742307692307692,13.161538461538463,13.580769230769231,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.19,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.37,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.71,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >